What is Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml?
Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is an antibiotic in a group of drugs called penicillins. Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) fights bacteria in the body.
Clavulanate potassium is a form of Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml), which is similar to penicillin. Clavulanate potassium fights bacteria that is often resistant to penicillins and other antibiotics.
The combination of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and clavulanate potassium is used to treat many different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.
Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and clavulanate potassium may also be used for purposes not listed in this medication guide.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml indications
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml-600 is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs ≤ 2 mcg/mL), H. influenzae (including β-lactamase–producing strains), or M. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors:
- antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following:
- age ≤ 2 years
- daycare attendance
NOTE: Acute otitis media due to S. pneumoniae alone can be treated with Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml). Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml-600 is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg/mL.
Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC ≤ 2 mcg/mL) and the β-lactamase–producing organisms listed above.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml-600 and other antibacterial drugs, Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml-600 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml description
Each film-coated tablet contains Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) trihydrate equivalent to Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 500 mg, and potassium clavulanate equivalent to Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 125 mg, respectively.
Each vial contains Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) sodium equivalent to Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 1000 mg and clavulanate potassium equivalent to Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 200 mg, respectively.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml tablets also contains the following excipients: Microcrystalline cellulose, sodium starch glycolate, anhydrous colloidal silica, povidone (K30), eudragit E 100, isopropyl alcohol, magnesium stearate, white opadryl 03B58965, PEG400, methylene chloride.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml is an antibacterial combination consisting of the semi-synthetic antibiotic Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)). Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Its molecular formula is C16H19N305S3H20 and the molecular weight is 419.46. Chemically, Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is (2S, 5R, 6R)-6-[(R)-(-)-2-Amino-2-(p-hydroxyphenyl) acetamido]-3, 3-dimethyl-7-oxo-4-1-azabicyclo[3.2.1] heptane-2-carboxylic acid trihydrate.
Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml): Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KN05 and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml dosage
Tablet: Tablets should be taken immediately before a meal.
General Information: For infections caused by Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)-sensitive organisms, the dosage is that approved for Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) as the Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) component does not contribute to the therapeutic effect.
Adults: 1 or 2 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 375 mg tab 8 hourly or 1 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 625 mg tab 8 hourly for more severe infections and infections of the respiratory tract.
For Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)-resistant organisms, the dosage of Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml tablets are as follows:
Since both Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 375 mg and 625 mg contain the same amount of Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) (125 mg, as the potassium salt), 2 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 375 mg are not equivalent to 1 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 625 mg. Therefore, 2 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 375 mg should not be substituted for 1 Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml 625 mg for treatment of more severe infections.
Renal Failure: Both Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) are excreted by the kidneys and the serum t½ of each increases in patients with renal failure. Therefore, the dose may need to be reduced or the interval extended. The following schedule in the dosage is proposed:
Haemodialysis decreases serum concentrations of both Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and an additional dose should be administered at the end of dialysis.
Oral Suspension:
Suspensions should be taken immediately before a meal.Reconstitution: For reconstitution to 30 mL, add water till the mark, invert the bottle and shake well until all the powder is dispersed.
Children: 25-50 mg/kg/day of the 4 parts Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml), 1 part Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) preparations (which corresponds to a daily dosage of the equivalent of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 20-40 mg/kg and Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) 5-10 mg/kg) to be taken in divided doses every 8 hrs at the start of a meal.
Dosage Guide:
To correspond to a dosage of 25-50 mg/kg/day.
To correspond to a dosage of 50 mg/kg/day.
IV/IM: Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml may be administered by the IV routes.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml is administered by IM or slow IV injection in doses of 500 mg every 8 hrs.
Severe Infections: 1 g every 6 hrs by slow IV injection over 3-4 min or by infusion over 30-60 min.
Children ≤10 years: 50-100 mg/kg body weight daily by injection in divided doses.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml interactions
See also:
What other drugs will affect Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml?
Probenecid decreases the renal excretion of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml). Concurrent use with Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml may result in increased and prolonged blood levels of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml).
The concurrent administration of allopurinol and ampicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. But it is not known whether this potentiation of ampicillin rash is due to allopurinol or the hyperuricemia present in these patients.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml should not be co-administrated with disulfiram.
Prolongation of bleeding time and prothrombin time have been reported in some patients receiving Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml. Thus, Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml should be used with care in patients on anticoagulation therapy.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml may reduce the effect of oral contraceptives and the caution should be given to patients.
Laboratory Test Interactions: Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml results in high urine concentration. High urine concentration of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest, Benedict or Fehling's solution.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml side effects
The most frequently reported adverse effects were diarrhoea, nausea, vomiting, abdominal pain, skin rashes, urticaria and erythema multiforme, vaginitis, abnormal taste, headache, dizziness, tiredness and hot flushes. The incidence and severity of adverse effects, particularly nausea and diarrhoea, increased with the higher recommended dose and can be minimised by administering the agent at the start of a meal. In addition, as these symptoms are especially related to the potassium clavulanate component, where these GI symptoms occur and a higher concentration of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) is required, consideration should be given to administering the additional Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) separately.
Hepatitis and cholestatic jaundice have been reported with the combination of Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) and Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml); the Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) component has been implicated. The events associated with Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml may be severe and occur predominantly in adult or elderly patients. Signs and symptoms usually occur during or shortly after treatment, but in some cases may not become apparent until several weeks after treatment has ceased. The hepatic events are usually reversible. However, in extremely rare circumstances, death has been reported. These have almost always been cases associated with serious underlying disease or concomitant medication.
A moderate rise in aspartate transaminase and/or alanine transaminase has been noted in patients treated with Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml, the significance of these findings is unknown.
The following adverse reactions have been reported for ampicillin class antibiotics and may occur with Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml.
Gastrointestinal: Gastritis, stomatitis, glossitis, black hairy tongue, enterocolitis and pseudomembranous colitis. If GI reactions are evident, they may be reduced by taking Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml at the start of a meal.
Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) causes hypersensitivity reactions similar to those induced by penicillin G and ampicillin, including rashes and fever. The incidence of these reaction is probably no higher than with other penicillins. Sensitivity reactions are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever or uticaria. Hypersensitivity reactions include skin rashes, urticaria, erythema multiforme, rare cases of Stevens-Johnson syndrome and less frequently exfoliative dermatitis and toxic epidermal necrolysis have been reported. Whenever such reactions occur, Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml should be discontinued. Serious and occasional fatal hypersensitivity (anaphylactic) reactions and angioneurotic oedema can occur with oral penicillin.
Haematopoietic and Lymphatic: Anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leucopenia and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in patients treated with Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml. Prolongation of bleeding time and prothrombin time have also been reported less frequently.
Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) alone or in combination with Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) has been associated with acute hepatic dysfunction. The incidence rate (95% confidence intervals) were 1.7 (1.1-2.7) (Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)-Clavulanic Acid (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)) and 0.3 (0.2-0.5)/10,000 prescriptions (Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml) alone). Risks were increased in patients receiving >1 course and in older recipients.
Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, behavioural changes and/or dizziness have also been reported. Depression, seizures or hallucinations.
Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml contraindications
Hypersensitivity to the Amoxicillin (Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml)/clavulanate potassium to any of the penicillins or to any of the excipients of Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml.
History of a severe immediate hypersensitivity reaction (eg, anaphylaxis) to another β-lactam agent (eg, a cephalosporin, carbapenem or monobactam).
History of cholestatic jaundice/hepatic dysfunction due to Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml.
Active ingredient matches for Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml:
Amoxicillin/Clavulanic Acid in France.
List of Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Amoxicilline; Clavulaanzuur | |
| Tablet; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid 50 mg | |
| Amoxiclav (Germany, Mexico) | |
| Tablet, Film-Coated; Oral; Amoxicillin Trihydrate; Clavulanic Acid / Clavulanate Potassium (Alpharma-isis) | |
| Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg (Alpharma-isis) | |
| Suspension; Oral; Amoxicillin Trihydrate 125 mg; Clavulanic Acid 31.25 mg / 5 ml (Alpharma-isis) | |
| Suspension; Oral; Amoxicillin Trihydrate 250 mg; Clavulanic Acid 62.5 mg / 5 ml (Alpharma-isis) | |
| Tablet; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid 125 mg (Alpharma-isis) | |
| AmoxiClav - 1 A Pharma (Germany) | |
| Amoxiclav Amneal (Australia) | |
| Amoxiclav Apotex (Belgium) | |
| Amoxiclav Aristo (Germany) | |
| Amoxiclav Basics (Germany) | |
| Amoxiclav beta (Germany) | |
| Amoxiclav BID (Mexico) | |
| Suspension; Oral; Amoxicillin Trihydrate 200 mg; Clavulanic Acid 28.57 mg / 5 ml | |
| Suspension; Oral; Amoxicillin Trihydrate 400 mg; Clavulanic Acid 57 mg / 5 ml | |
| Tablet; Oral; Amoxicillin Trihydrate 875 mg; Clavulanic Acid 125 mg | |
| Amoxiclav Forte | |
| Amoxiclav Hikma (Germany) | |
| Amoxiclav Juno (Australia) | |
| Amoxiclav multichem (New Zealand) | |
| Amoxiclav Mylan (Belgium) | |
| Amoxiclav Sandoz (Belgium, Luxembourg) | |
| Amoxiclav Sandoz 1000mg/200mg (Luxembourg) | |
| Amoxiclav Sandoz 125mg/31.25mg/5ml (Luxembourg) | |
| Amoxiclav Sandoz 2000mg/200mg (Luxembourg) | |
| Amoxiclav Sandoz 250mg/62.5mg/5ml (Luxembourg) | |
| Amoxiclav Sandoz 500mg/125mg (Luxembourg) | |
| Amoxiclav Sandoz 875mg (Luxembourg) | |
| Amoxiclav Teva (Belgium, Israel, Switzerland) | |
| AmoxiClav-1A Pharma (Germany) | |
| Amoxiclav-CT (Germany) | |
| AmoxiClav-Denk (Georgia) | |
| Amoxiclav-Puren (Germany) | |
| Amoxiclav-VMD (Belgium) | |
| Amoxiclav-VMD 250mg voor honden (Netherlands) | |
| Amoxiclav-VMD 500mg voor honden (Netherlands) | |
| Amoxiclav-VMD 50mg voor honden en katten (Netherlands) | |
| AmoxiClavulan (Austria) | |
| AmoxiClavulan 1A Pharma (Austria) | |
| Amoxiclin-CL (Peru) | |
| Amoxiclin-CL 12h (Peru) | |
| Amoxicomp (Austria) | |
| Amoxicomp Genericon (Austria) | |
See 7042 substitutes for Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml | |
References
- DailyMed. "AMOXICILLIN; CLAVULANATE POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "CLAVULANIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "amoxicillin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Amoxicilline Acide Clavulanique Zydus France Enfants 100 mg/12,5 mg/ml. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
